<DOC>
	<DOCNO>NCT02876107</DOCNO>
	<brief_summary>The goal clinical research study learn add panitumumab combination carboplatin paclitaxel help control IBC give standard chemotherapy surgery . The safety drug combination also study .</brief_summary>
	<brief_title>A Phase II Study Using Panitumumab/Carboplatin/Paclitaxel ( PaCT ) Followed Anthracycline-Containing Regimen ( AC ) New Triple-Negative Inflammatory Breast Cancer ( TN-IBC )</brief_title>
	<detailed_description>Study Groups : If participant find eligible take part study , randomly assign ( flip coin ) 1 2 study group . Participant equal ( 50/50 ) chance assign either group , participant study staff know participant receiving : - If participant Group A , receive panitumumab , carboplatin , paclitaxel , follow doxorubicin cyclophosphamide . - If participant Group B , receive carboplatin paclitaxel , follow doxorubicin cyclophosphamide . Study Drug Administration : Every study cycle 21 day . Participant receive paclitaxel vein 1-3 hour Days 1 , 8 , 15 Cycles 1-4 . Participant receive carboplatin vein 30 minute Day 1 Cycles 1-4 . If participant Group A , also receive panitumumab vein . Participant first receive 1 hour Day 1 1-week `` pre-cycle . '' Participant receive 30 minute Days 1 , 8 , 15 Cycles 1-4 , receive paclitaxel . Participant receive standard care doxorubicin cyclophosphamide vein 90 minute Day 1 Cycles 5-8 . This schedule may change study doctor think need . Study Visits : For Groups A B : - Every day participant receives study drug , time surgery last dose doxorubicin cyclophosphamide , blood ( 1Â½ 3 tablespoon ) draw routine test . - Before cycle , time surgery last dose doxorubicin cyclophosphamide , participant physical exam include breast lymph node exam . - On Day 1 Cycle 1 , 1 time participant begin receive doxorubicin cyclophosphamide , 1 time surgery , study doctor take picture participant 's breast . - Before receive treatment , Day 1 Cycle 1 , 1 time participant begin receive doxorubicin cyclophosphamide , 1 time surgery , blood ( 5 tablespoon ) draw cytokine testing . - One ( 1 ) time participant begin receive doxorubicin cyclophosphamide , mammogram involve breast ultrasound involve breast lymph node . Participant may breast MRI doctor think need . If participant Group A , breast core biopsy Day 1 Cycle 1 biomarker test . This schedule may change study doctor think need . Surgery : After participant finish receive doxorubicin cyclophosphamide , standard care surgery . Participant give separate consent form read sign . During surgery , breast tissue sample collect identify tumor routine test biomarker test . Length Study : Participant may continue take study drug 8 cycle . Participant longer able take study drug disease get bad , intolerable side effect occur , unable follow study direction . Patient 's participation study follow-up period . Follow-Up : About 1 month surgery , participant ask health side effect may . Participant may ask routine clinic visit may call member study staff . If participant call , call last 2 minute . One ( 1 ) time every year least 5 year participant stop take study drug , contact ask . If participant call , call last 2 minute . This may also do regular clinic visit . This investigational study . Panitumumab FDA approve commercially available treatment epidermal growth factor receptor ( EGFR ) -expressing metastatic colorectal cancer disease progression . Paclitaxel , carboplatin , doxorubicin cyclophosphamide FDA approve commercially available treatment breast cancer . The addition panitumumab combination carboplatin paclitaxel investigational currently use research purpose . The study doctor describe study drug design work . Up 72 participant enrol study . All take part MD Anderson .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Inflammatory Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Patients must histological confirmation breast carcinoma . 2 . Patients must IBC , confirm accord international consensus criterion : a. Onset : Rapid onset breast erythema , edema , and/or peau d'orange , and/or warm breast , without underlie breast mass b . Duration : History finding 6 month c. Extent : Erythema occupy least 1/3 whole breast d. Pathology : Pathologic confirmation invasive carcinoma 3 . Patients must Eastern Cooperative Oncology Group ( ECOG ) performance status 01 . 4 . Patients must negative HER2 expression IHC ( define 0 1+ ) fluorescence situ hybridization ( FISH ) analysis . If HER2 2+ , negative HER2 expression must confirm FISH ( HER2/cep17 ration &lt; 2 , and/or copy number le 6 ) . ER progesterone receptor ( PgR ) expression le 10 % . 5 . Patients must 18 year age old . 6 . Patients leave ventricular ejection fraction ( LVEF ) &gt; =50 % multigated acquisition scan ( MUGA ) echocardiogram study randomization 7 . Patients adequate hematologic function : absolute neutrophil count ( ANC ) &gt; =1.5 x 10^9/L , platelet count &gt; =100 x 10^9/L , hemoglobin &gt; = 9.0 g/dL . 8 . Patients adequate hepatic function : aspartate aminotransferase ( AST ) = &lt; 3.0 x upper limit normal ( ULN ) , alanine aminotransferase ( ALT ) = &lt; 3.0 x ULN , alkaline phosphatase ( ALP ) = &lt; 2.5 x ULN , total bilirubin = &lt; 1.5 x ULN 9 . Patients adequate renal function : creatinine ( Cr ) = &lt; 1.5 mg/dL x ULN , creatinine clearance ( CrCl ) &gt; = 50 mL/min calculate CockcroftGault method follow : male creatinine clearance = ( 140 age year ) x ( weight kg ) / ( serum Cr x 72 ) ; female CrCl = ( 140 age year ) x ( weight kg ) x 0.85 / ( serum Cr x 72 ) . 10 . Patients ability willingness sign write informed consent . 11 . Patients childbearing potential ( woman postmenopausal &lt; 1 year , surgically sterilize , abstinent ) , negative urine pregnancy test , agree consistent correct use one follow acceptable method birth control : male partner sterile female subject 's entry study sole sexual partner female subject ; intrauterine device , oral contraception , barrier method , include diaphragm condom spermicide 1 . Stage IV disease , metastatic site amendable local therapy ( i.e . radiation and/or surgery ) , candidate breast surgery eligible . 2 . History radiotherapy current breast cancer diagnosis . 3 . History recent malignancy &lt; 5 year ( except cure nonmelanomatous skin cancer cure cervical carcinoma situ ) 4 . Known positive test ( ) human immunodeficiency virus infection , hepatitis C virus , acute chronic active hepatitis B infection . 5 . History extensive interstitial lung disease , e.g. , pneumonitis pulmonary fibrosis evidence extensive interstitial lung disease baseline chest CT scan . 6 . Other known significant medical psychiatric condition would make assessment toxicity efficacy difficult . 7 . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement 8 . Patients peripheral neuropathy &gt; grade 1 . 9 . Patients history New York Heart Association class 3 4 heart failure , history myocardial infarction , unstable angina , cerebrovascular accident ( CVA ) within 6 month protocol registration . 10 . Patients history prior therapy carboplatin . 11 . Patients receive cumulative dose doxorubicin great 360 mg/m2 epirubicin great 640 mg/m2 . 12 . Patients prior radiotherapy primary breast carcinoma axillary lymph node . 13 . Patients history diagnose interstitial lung disease .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Malignant neoplasm breast</keyword>
	<keyword>Breast cancer</keyword>
	<keyword>Newly diagnose primary triple-negative inflammatory breast cancer</keyword>
	<keyword>Inflammatory breast cancer</keyword>
	<keyword>IBC</keyword>
	<keyword>TN-IBC</keyword>
	<keyword>Breast biopsy</keyword>
	<keyword>Mammogram</keyword>
	<keyword>Ultrasound</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>Taxol</keyword>
	<keyword>Carboplatin</keyword>
	<keyword>Paraplatin</keyword>
	<keyword>Panitumumab</keyword>
	<keyword>Vectibix</keyword>
	<keyword>Doxorubicin</keyword>
	<keyword>Doxorubicin Hydrochloride</keyword>
	<keyword>Adriamycin PFS</keyword>
	<keyword>Adriamycin RDF</keyword>
	<keyword>Adriamycin</keyword>
	<keyword>Rubex</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Cytoxan</keyword>
	<keyword>Neosar</keyword>
</DOC>